As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT), a forward-thinking innovator in health…
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal…
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal…
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal…
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action…
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action…
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal…
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action…
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action…